The problem was that the trial also showed that Invokana almost doubled the risk of lower limb amputations, and that was added to the product’s label as a ‘black box’ warning. Cue a decline ...

Johnson & Johnson's SGLT2 inhibitor Invokana has been shown to have a significant effect on heart failure symptoms in a clinical trial that relied entirely on remote monitoring of symptoms using a ...